‘Pomalyst’ applied for insurance benefit while 48 products removed
From January next year, ‘Pomalyst Cap,’ a multiple myeloma treatment, will be applied for the health insurance benefit under the risk sharing(return type) application, and ‘Sunpla,’ a Korean new drug, will be removed from the benefit.
The Ministry of Health and Welfare(MOHW) announced a partial ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
